News Headlines
-
AbbVie And OSE Immunotherapeutics Announce Partnership To Develop A Novel Monoclonal Antibody For The Treatment Of Chronic Inflammation
2/28/2024
AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, today announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.
-
Simtra BioPharma Solutions Announces $250+M Investment To Expand Sterile Fill/Finish Manufacturing Site In Bloomington, Indiana
2/28/2024
Simtra BioPharma Solutions (Simtra), a premier injectable contract development and manufacturing organization (CDMO), today announced a $250+ million expansion of its sterile fill/finish manufacturing campus in Bloomington, Indiana.
-
Amneal Enters Into Exclusive European Licensing Agreement With Zambon Biotech For IPX203
2/27/2024
Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group (“Zambon”), for IPX203 in the European Union, United Kingdom, and Switzerland.
-
Experic Expands Global Clinical Trial Storage And Logistics Services To Europe
2/27/2024
Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry, announced its new facility in Dublin, Ireland, to support global clinical trials.
-
Telix Expands U.S. Development And Manufacturing Infrastructure With Acquisition Of IsoTherapeutics
2/27/2024
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services to many companies in the radiopharmaceutical industry, including Telix.
-
BioCina And NovaCina Forge Strategic Alliance To Offer Biologics Developers Integrated Drug Substance And Drug Product Solutions
2/27/2024
BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide integrated drug substance and drug product solutions for biologics developers.
-
Takeda Accelerates Access To Its Dengue Vaccine Through 'Make In India' Manufacturing Partnership With Biological E.
2/27/2024
Takeda (TSE:4502/NYSE:TAK) today announced a strategic partnership with Biological E. Limited, a leading vaccines and biologics company in India, to manufacture Takeda's dengue vaccine, TAK-003.
-
Microsize Announces Expanded CDMO Relationship With Cerus Corporation
2/26/2024
Microsize today announced the signing of a long-term supply agreement with Cerus Corporation to provide high-throughput particle sizing services for the functional powders used in the INTERCEPT Blood System for Plasma, a pathogen inactivation technology used by blood centers around the world to help safeguard the blood supply.
-
GC Cell And BioCentriq® Execute Process Transfer Agreement In Anticipation Of The U.S. Entry Of Immuncell-LC Inj.
2/26/2024
GC Cell, a fully integrated cell therapy pioneer has announced a strategic partnership with BioCentriq, a cell therapy contract development and manufacturing organization (CDMO) and US affiliate of GC Cell.
-
Pharmascience Expands Its Contract Development And Manufacturing Organization (CDMO) Services With A New Commercial Business Unit
2/26/2024
Last Fall, Pharmascience, the largest Canadian-owned pharmaceutical company, announced a major $120M sterile injectable manufacturing facility expansion at its Candiac site.